Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial

• Ajay Kumar ,

  * E-mail: drajaykr@yahoo.com

  Affiliation Diabetes Care & Research Centre, Near Overbridge, Kankarbagh, Patna, Bihar, India

  ⨯
• Edward Franek,

  Affiliation Medical Research Center, Polish Academy of Sciences and Central Clinical Hospital MSWiA, Warsaw, Poland

  ⨯
• Jonathan Wise,

  Affiliation Tulane Medical School, Department of Endocrinology, New Orleans, LA, United States of America

  ⨯
• Marcus Niemeyer,

  Affiliation Market Access and Public Affairs, Novo Nordisk Pharma GmbH, Mainz, Germany

  ⨯
• Henriette Mersebach,

  Affiliation Clinical Development & Research–Diabetes & Obesity, Novo Nordisk Inc, Princeton, NJ, United States of America

  ⨯
• Rafael Simó

  Affiliation Diabetes and Metabolism Research Unit, Autonomous University of Barcelona, Vall d’Hebron Institute de Recerca, and CIBERDEM, Barcelona, Spain

  ⨯